DANYELZA

PeakmAb

naxitamab

Y-mAbs Therapeutics
BLAINTRAVENOUSSOLUTIONPriority Review
Approved
Nov 2020
Lifecycle
Peak
Competitive Pressure
30/100

Mechanism of Action

Glycolipid Disialoganglioside-directed Antibody Interactions

Pharmacologic Class:

Glycolipid Disialoganglioside-directed Antibody

Company
Y-mAbs Therapeutics
Y-mAbs Therapeutics
NY - New York
1 open job
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers